



Hikma Pharmaceuticals Remains Constituent of FTSE4Good Sustainability Index

London, August 2017 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, continues to be recognized as a constituent of the FTSE4Good Index Series for positive environmental, social and governance practices.

Founded on solid philanthropic principles with a strong commitment to employees, its communities and the environment, Hikma has consistently emphasized the importance of operating sustainably by engaging with stakeholders, minimizing its environmental impact and improving transparency.

“We are pleased to remain a constituent member of the FTSE4Good Sustainability Index in recognition of our commitment to the highest ethical principles and code of conduct. In addition to cultivating our values of integrity, excellence and transparency, we also endeavor to ensure that all our stakeholders adopt the policies, behaviours, and high levels of ethical business practices undertaken by Hikma,” said Hana Darwazeh Ramadan, Vice President of Corporate Communication and Corporate Responsibility at Hikma Pharmaceuticals, “We strive to continuously create positive impact and preserve our standing as an active player in the international arena of global welfare and ethics.”

Hikma has been an active member of the UN Global Compact (UNGC) since 2007, a voluntary coalition of some 9,500 institutions in 162 countries comprising businesses, public-sector organizations, NGOs, academic institutions, cities and municipalities among others. Hikma’s values are closely aligned with the UNGC’s principles in the areas of human rights, labor, environment and anti-corruption.

- End -

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: “Branded”, “Injectables” and “Generics”, based primarily in the Middle East and North Africa (“MENA”) region, where it is a market leader, the United States and Europe. Hikma currently employs over 8,500 staff members worldwide.

For further information and latest news updates, visit www.Hikma.com or contact:

Hana Darwazeh Ramadan

Email: Media@Hikma.com

Tel: +962 6 580 2900